T

    Tvardi Therapeutics, Inc. (TVRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.80
    -0.02 (-1.10%)

    Market Cap: $24.28M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(21/33)
    Avg Surprise
    -175.46%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.59
    Range$-1.06 - $-0.28
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.48+17.6%
    60d ago$-0.54+8.4%
    30d ago$-0.53+10.3%
    7d ago$-0.53+10.3%
    Current$-0.59
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.44
    Range$-1.09 - $0.33
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.44---
    Sep 26EST
    		-$-0.59---
    Jun 26
    		$-0.69$-0.65-6.15%Miss-235.3%
    Mar 26
    		$-0.73$-0.65-12.31%Miss-46.0%
    Dec 25
    		$-0.78$-0.57-36.84%Miss+85.0%
    Sep 25
    		$-0.59$-0.81+27.16%Beat+92.8%
    Jun 25
    		$0.51$-0.39+230.77%Beat+288.9%
    Mar 25
    		$-0.50$-0.58+13.79%Beat+10.7%
    Dec 24
    		$-5.21$-0.20-2548.70%Miss-783.1%
    Sep 24
    		$-8.19$-0.24-3312.25%Miss-1474.9%
    Jun 24
    		$-0.27$-0.26-3.85%Miss+53.4%
    Mar 24
    		$-0.56$-0.40-40.00%Miss-14.3%
    Dec 23
    		$-0.59$-0.45-31.11%Miss-5.4%
    Sep 23
    		$-0.52$-0.52+0.00%Beat-20.9%
    Jun 23
    		$-0.58$-0.54-7.41%Miss-625.0%
    Mar 23
    		$-0.49$-0.51+3.92%Beat+5.8%
    Dec 22
    		$-0.56$-0.32-75.00%Miss+11.1%
    Sep 22
    		$-0.43$-0.43+0.00%Beat-2050.0%
    Jun 22
    		$-0.08$-0.08+0.00%Beat+86.9%
    Mar 22
    		$-0.52$-0.52+0.00%Beat-10.6%
    Dec 21
    		$-0.63$-0.63+0.00%Beat-139.6%
    Sep 21
    		$-0.02$-0.02+0.00%Beat+94.3%
    Jun 21
    		$-0.61$-0.61+0.00%Beat-13.0%
    Mar 21
    		$-0.47$-0.47+0.00%Beat+24.2%
    Dec 20
    		$1.59$1.59+0.00%Beat+360.7%
    Sep 20
    		$-0.35$-0.35+0.00%Beat+52.7%
    Jun 20
    		$-0.54$-0.54+0.00%Beat+6.9%
    Mar 20
    		$-0.62$-0.62+0.00%Beat-10.7%
    Dec 19
    		$-0.61$-0.61+0.00%Beat-17.3%
    Sep 19
    		$-0.74$-0.74+0.00%Beat-45.1%
    Jun 19
    		$-0.58$-0.58+0.00%Beat-11.5%
    Mar 19
    		$-0.56$-0.58+3.45%Beat+97.0%
    Dec 18
    		$-0.52$-0.58+10.34%Beat+96.7%
    Sep 18
    		$-0.51$-0.49-4.08%Miss+96.3%
    Jun 18
    		$-0.52$-0.51-1.96%Miss+95.0%
    Mar 18
    		$-18.47N/AN/ABeat+36.9%
    Dec 17
    		$-15.64N/AN/ABeat+46.0%
    Sep 17
    		$-13.75N/AN/ABeat+9.7%
    Jun 17
    		$-10.38N/AN/ABeat-
    Mar 17
    		$-29.28N/AN/ABeat-
    Dec 16
    		$-28.98N/AN/ABeat-
    Sep 16
    		$-15.23N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.65EV/EBITDAN/A
    Price/FCF-0.67xFCF Yield-148.22%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-126.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.87xQuick Ratio1.87x
    Trading Statistics
    BetaN/AAvg Volume204.35K
    52-Week High$43.6552-Week Low$1.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.83
    SMA 20$1.84
    SMA 50$2.31
    SMA 200$3.37
    EMA 10$1.83
    EMA 20$1.93
    EMA 50$2.27
    EMA 200$5.44

    MACD

    Line: -0.16Signal: -0.19Hist: 0.03

    ADX

    ADX: 10.1+DI: 21.7-DI: 19.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down40.0
    PSAR$2.04

    Bollinger Bands

    Upper Band$1.99
    Lower Band$1.69
    %B Position1611%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    39.3

    Momentum Oscillators

    Stoch %K28.4
    Stoch %D28.9
    Williams %R-77.4
    ROC (10d)-3.2%
    Momentum-0.06
    CCI (20d)-64.0
    MFI (14d)66.2

    Volatility Measures

    ATR (14d)$0.18(9.8%)
    StdDev (20d)0.07
    Hist Vol50.9%(High)

    Volume Flow

    VWAP$1.80
    OBV89.5M
    AD Line78.5M
    CMF (20d)-0.206

    Volume Metrics

    Avg Vol (20d)203.8K
    Vol Ratio0.6x
    VWMA (20d)$1.86

    Pivot Points

    R3$2.04
    R2$1.98
    R1$1.90
    Pivot Point$1.84
    S1$1.76
    S2$1.70
    S3$1.62

    Advanced Oscillators

    TSI-22.80
    Ultimate Osc34.9
    KST-218.48

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-2,569,000$0$0$0$-2,135,000$0$0$2.13M$3.00M$4.87M
    Cost of Revenue$0$0N/A$0$0$0$-620,000$0$0$620,000$608,000$1.56M
    Gross Profit$0$0$-2,569,000$0$0$0$-1,515,000$0$0$1.51M$2.40M$3.31M
    Operating Expenses$6.63M$7.05M$6.99M$5.94M$8.87M$4.35M$-15,931,000$5.68M$7.18M$31.18M$35.00M$32.21M
    R&D$4.00M$4.91M$8.28M$3.60M$5.81M$3.11M$-9,640,000$4.79M$6.53M$21.96M$28.41M$25.45M
    SG&A$2.63M$2.14M$-1,297,000$2.33M$3.06M$1.24M$-3,890,000$881,000$650,000$6.82M$6.59M$6.75M
    Operating Income$-6,629,000$-7,051,000$-9,555,000$-5,938,000$-8,869,000$-4,354,000$14.42M$-5,676,000$-7,181,000$-29,666,000$-32,607,000$-28,898,000
    Interest Income$172,000$247,000$0$411,000$377,000$275,000$0$163,000$206,000$0$0$0
    Interest Expense$0$0$9.55M$0$0$5.22M$0$0$0$1.98M$604,000$0
    Income Before Tax$-6,457,000$-6,804,000$-19,107,000$-5,527,000$4.17M$-9,579,000$15.82M$-5,513,000$-6,975,000$-30,696,000$-30,610,000$-28,898,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,457,000$-6,804,000$-11,948,000$-5,527,000$4.17M$-9,579,000$13.79M$-5,513,000$-6,975,000$-30,696,000$-32,337,000$-28,032,000
    EBITDA$-6,620,000$-7,062,000$-9,565,000$-5,939,000$3.74M$-9,901,000$14.44M$-5,652,000$-6,666,000$-29,182,000$-32,766,000$-28,942,000
    EBIT$-6,629,000$-7,051,000$-9,555,000$-5,938,000$3.79M$-9,854,000$14.42M$-5,676,000$-7,181,000$-28,714,000$-32,607,000$-28,898,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TVRD

    News

    Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

    Tvardi Therapeutics announced its second-quarter 2026 financial results and provided a business update, highlighting positive topline results for its next-generation STAT3 inhibitor, TTI-109. The company has selected ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar to discuss its clinical potential. Tvardi reported a net loss of $6.5 million for Q2 2026 and expects its current cash to fund operations through the third quarter of 2027, with additional funding needed for TTI-109's advancement in UC.

    Sahm•8/14/26•
    Somewhat-Bullish

    Tvardi Therapeutics (TVRD) plans up to $9.7M Nasdaq at-the-market stock offering

    Tvardi Therapeutics (TVRD) is launching an at-the-market equity program to sell up to $9.7 million of common stock through JonesTrading. The proceeds are intended for general corporate purposes, including clinical trials, research and development, and potential in-licensing or acquisitions. This offering could result in the issuance of up to 3,146,027 new shares, leading to an illustrative dilution of $0.91 per share for existing holders.

    Stock Titan•7/18/26•
    Somewhat-Bearish

    Cara Therapeutics Inc. (CARA) Q1 2022 Earnings Call Transcript

    Cara Therapeutics discussed its Q1 2022 financial results and commercial launch progress for KORSUVA injection in the U.S., highlighting initial positive reception and ordering by dialysis clinics. The company also announced the European approval of Kapruvia, triggering a $15 million milestone payment, and provided updates on its Oral KORSUVA Phase 3 programs and earlier-stage pipeline.

    AlphaStreet•7/18/26•
    Neutral

    Cara Therapeutics

    Cara Therapeutics is a clinical-stage biotechnology company focusing on developing new chemical entities to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Their lead candidate, Korsuva (CR845/difelikefalin), a first-in-class k-opioid receptor agonist, has shown significant reductions in itch intensity and improved quality of life in hemodialysis patients with chronic kidney disease-associated pruritus. The company recently announced a collaboration with Tvardi on antifibrotics and previously received FDA approval for Korsuva for pruritus in hemodialysis patients.

    The Pharma Letter•6/30/26•
    Somewhat-Bullish

    What's Going On With Cara Therapeutics Stock?

    Cara Therapeutics shares saw an 11.5% increase after the company announced it hired Piper Sandler & Co. to explore strategic alternatives to enhance shareholder value. CEO Christopher Posner stated the company is evaluating options while also implementing cost-containment measures. While there's no guarantee of agreements, the company reported having approximately $70 million in cash and marketable securities as of March 31.

    TradingView•6/10/26•
    Neutral

    Frequently Asked Questions About TVRD

    Does TVRD pay dividends?
    Tvardi Therapeutics, Inc. (TVRD) does not currently pay a regular dividend.
    What is TVRD's market cap?
    Tvardi Therapeutics, Inc. (TVRD) has a market capitalization of $24.28M with a current stock price of $1.80.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In